Continuing the search for a hormonal male contraceptive.


Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 31 12 2019
revised: 28 01 2020
accepted: 09 02 2020
pubmed: 22 3 2020
medline: 28 7 2020
entrez: 22 3 2020
Statut: ppublish

Résumé

This chapter discusses the mechanisms of action of hormonal male contraception, which suppresses the hypothalamic-pituitary-testis axis. When the intratesticular concentration of testosterone is subsequently suppressed to adequately low concentrations, spermatogenesis is arrested. Androgens are a necessary hormonal male contraceptive component because they not only suppress the hypothalamic-pituitary-testis axis, but also provide the male hormone necessary to maintain peripheral androgen functions. Past studies using testosterone alone and testosterone combined with progestins demonstrated contraceptive efficacy in the female partner at rates similar to combined hormonal female methods. Newer hormonal male contraceptive formulations and the alternative routes of administration are discussed, along with potential barriers, challenges, and opportunities for hormonal male contraceptive development. Novel methods that are safe, effective, reversible, user-friendly, and coitus-independent are intrinsic to equitably meet the various needs and limitations of an increasingly diverse population.

Identifiants

pubmed: 32197832
pii: S1521-6934(20)30030-4
doi: 10.1016/j.bpobgyn.2020.02.003
pmc: PMC7375909
mid: NIHMS1590630
pii:
doi:

Substances chimiques

Androgens 0
Contraceptive Agents, Male 0
Testosterone 3XMK78S47O

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-94

Subventions

Organisme : NICHD NIH HHS
ID : F32 HD097932
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors received support for clinical trials under the Contraceptive Clinical Trials Network, Eunice Shriver National Institute of Child Health and Human Development (HHSN275201300024I), National Institutes of Health, Bethesda, USA. Dr. Yuen is a recipient of a F32HD097932 fellowship award from Eunice Shriver National Institute of Child Health and Human Development.

Références

Lancet. 2006 Apr 29;367(9520):1412-20
pubmed: 16650651
J Clin Endocrinol Metab. 2003 Feb;88(2):562-8
pubmed: 12574181
J Clin Endocrinol Metab. 2016 Dec;101(12):4779-4788
pubmed: 27788052
Andrology. 2019 Nov;7(6):878-887
pubmed: 30969032
Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):605-13
pubmed: 23186401
Physiol Rev. 1972 Jan;52(1):198-236
pubmed: 4621362
J Clin Endocrinol Metab. 1993 Aug;77(2):427-32
pubmed: 8345047
J Clin Endocrinol Metab. 1992 Aug;75(2):393-8
pubmed: 1639941
J Clin Endocrinol Metab. 2003 Oct;88(10):4659-67
pubmed: 14557437
J Biosoc Sci. 2017 Sep;49(5):648-663
pubmed: 27890042
J Clin Endocrinol Metab. 1985 May;60(5):998-1003
pubmed: 3920237
J Urol. 2012 Dec;188(6 Suppl):2482-91
pubmed: 23098786
J Clin Endocrinol Metab. 1979 Oct;49(4):520-6
pubmed: 479345
Endocr Rev. 2009 Apr;30(2):119-32
pubmed: 19176467
Lancet. 1990 Oct 20;336(8721):955-9
pubmed: 1977002
J Clin Endocrinol Metab. 2019 Mar 1;104(3):629-638
pubmed: 30252057
Hum Reprod. 2010 Apr;25(4):853-61
pubmed: 20139122
J Clin Endocrinol Metab. 2009 Jul;94(7):2313-20
pubmed: 19366848
Andrology. 2019 Mar;7(2):235-243
pubmed: 30556332
J Androl. 2004 Nov-Dec;25(6):931-8
pubmed: 15477366
Best Pract Res Clin Obstet Gynaecol. 2014 Aug;28(6):845-57
pubmed: 24947599
Hum Reprod Update. 2016 Sep;22(5):634-46
pubmed: 27307386
Urology. 2018 Aug;118:76-79
pubmed: 29578040
MMWR Morb Mortal Wkly Rep. 2016 Jun 17;65(23):602-5
pubmed: 27309884
Contraception. 2011 May;83(5):397-404
pubmed: 21477680
J Androl. 2011 Mar-Apr;32(2):183-92
pubmed: 20798389
J Clin Endocrinol Metab. 2008 Jul;93(7):2572-80
pubmed: 18413423
J Clin Endocrinol Metab. 2009 Jun;94(6):1910-5
pubmed: 19293262
J Clin Endocrinol Metab. 1992 Jan;74(1):84-90
pubmed: 1727833
Ther Adv Endocrinol Metab. 2019 Mar 14;10:2042018819834846
pubmed: 30899448
Hum Reprod. 2000 Mar;15(3):646-9
pubmed: 10686212
Hum Reprod. 2005 Feb;20(2):549-56
pubmed: 15608042
J Clin Endocrinol Metab. 2003 Nov;88(11):5232-9
pubmed: 14602755
J Androl. 2007 May-Jun;28(3):362-3
pubmed: 17192594
J Clin Endocrinol Metab. 1992 Aug;75(2):476-83
pubmed: 1639948
J Clin Endocrinol Metab. 2019 Feb 1;104(2):423-432
pubmed: 30252061
Andrology. 2016 Sep;4(5):773-5
pubmed: 27529489
J Clin Endocrinol Metab. 2004 May;89(5):2254-62
pubmed: 15126550
Perspect Sex Reprod Health. 2017 Mar;49(1):7-16
pubmed: 28245088
Fertil Steril. 1996 Mar;65(3):626-36
pubmed: 8774299
J Androl. 2012 Mar-Apr;33(2):190-201
pubmed: 21474786
J Androl. 2005 Mar-Apr;26(2):155-62
pubmed: 15713817
Fertil Steril. 1996 Apr;65(4):821-9
pubmed: 8654646
J Androl. 1999 May-Jun;20(3):407-14
pubmed: 10386821
J Clin Endocrinol Metab. 2012 Oct;97(10):3476-86
pubmed: 22791756
Metabolism. 1999 May;48(5):590-6
pubmed: 10337859
Contraception. 2016 Jul;94(1):11-7
pubmed: 27018154
Curr Opin Urol. 2010 Nov;20(6):520-4
pubmed: 20808223
Contraception. 2010 Nov;82(5):453-6
pubmed: 20933119
J Androl. 2011 Sep-Oct;32(5):530-40
pubmed: 21164142
J Clin Endocrinol Metab. 1997 May;82(5):1403-8
pubmed: 9141524
Rev Endocr Metab Disord. 2011 Jun;12(2):107-17
pubmed: 21547529
Biol Reprod. 2017 Aug 1;97(2):182-188
pubmed: 29044431
Andrology. 2017 Mar;5(2):278-285
pubmed: 27907978
Andrology. 2014 Jul;2(4):579-587
pubmed: 24789057
J Androl. 2010 Sep-Oct;31(5):472-81
pubmed: 20378929
Metabolism. 1990 Jan;39(1):69-74
pubmed: 2294373
Urology. 2015 Apr;85(4):819-25
pubmed: 25817104
J Androl. 2003 Jul-Aug;24(4):466-83
pubmed: 12826683
Clin Endocrinol (Oxf). 1984 Feb;20(2):119-28
pubmed: 6232019
Fertil Steril. 1995 Jul;64(1):139-45
pubmed: 7789550
J Clin Endocrinol Metab. 2008 May;93(5):1774-83
pubmed: 18303073

Auteurs

Fiona Yuen (F)

Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, 90509, USA. Electronic address: fiona.yuen@lundquist.org.

Brian T Nguyen (BT)

Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90007, USA. Electronic address: Nguyenbt@usc.edu.

Ronald S Swerdloff (RS)

Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, 90509, USA.

Christina Wang (C)

Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, 90509, USA. Electronic address: wang@lundquist.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH